PUMA BIOTECHNOLOGY, INC. (PBYI) Market Cap & Valuation Ratios
PUMA BIOTECHNOLOGY, INC. (PBYI) has a market cap of $568.9M, a trailing P/E of 21.2 and a price-to-sales ratio of 2.5, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PBYIPUMA BIOTECHNOLOGY, INC.Follow PBYI — free
—
Price chart with a free account
- Market cap
- 568.9M
- P/E TTM
- 21.2
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Peers
drug manufacturers - general · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| PBYI | 0.6 | 21.2 | 2.1 | 11.6 | 7.2% | -3% | 13% | 27% |
| NVCT | 0.7 | — | — | — | — | — | — | — |
| GYRE | 0.7 | — | 5.0 | — | -0.9% | +17% | -14% | -28% |
| AKTX | 0.6 | — | — | — | -1.6% | — | — | -175% |
| STTK | 0.6 | — | 487.7 | — | -7.5% | -67% | — | -72% |
| CBIO | 0.5 | — | 25.6 | — | — | — | — | — |
| DMAC | 0.5 | — | — | — | -6.7% | — | — | -139% |
| OVID | 0.4 | — | 192.4 | — | -13.0% | -76% | — | -52% |
| ASMB | 0.4 | — | 1.1 | — | -9.5% | +125% | -12% | -3% |
| RZLT | 0.4 | — | — | — | — | — | — | -105% |
| NBP | 0.4 | — | — | — | -5.6% | — | — | -587% |
| Median of these 10 | — | 25.6 | — | -6.7% | -25% | -13% | -89% |
; EV/Sales 2.1 vs. 25.6. PBYI's own P/E sits at the 83rd percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesPUMA BIOTECHNOLOGY, INC. — questions
- What is PUMA BIOTECHNOLOGY, INC.'s market cap?
- $568.9M.
- What is PUMA BIOTECHNOLOGY, INC.'s P/E ratio?
- 21.2 on trailing twelve-month earnings to 2026-06-30.
- What is PUMA BIOTECHNOLOGY, INC.'s price-to-sales ratio?
- 2.5.
Every figure on this page comes from PUMA BIOTECHNOLOGY, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.